CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 76.20M | 113.63M | 141.10M | 147.56M | 138.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.20M | 113.63M | 141.10M | 147.56M | 138.10M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 76.20M | 113.63M | 141.10M | 147.56M | 138.10M |
| SG&A Expenses | 28.74M | 28.10M | 29.63M | 31.40M | 29.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.77M | 90.39M | 97.98M | 111.60M | 113.11M |
| Operating Income | -19.57M | 23.25M | 43.13M | 35.96M | 25.00M |
| Income Before Tax | -17.13M | 28.26M | 48.23M | 41.84M | 32.09M |
| Income Tax Expenses | 237.00K | 245.00K | 248.00K | 236.00K | 223.00K |
| Earnings from Continuing Operations | -17.37 | 28.02 | 47.98 | 41.60 | 31.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.37M | 28.02M | 47.98M | 41.60M | 31.87M |
| EBIT | -19.57M | 23.25M | 43.13M | 35.96M | 25.00M |
| EBITDA | -18.19M | 24.53M | 44.70M | 37.65M | 26.76M |
| EPS Basic | 0.01 | 0.40 | 0.56 | 0.48 | 0.38 |
| Normalized Basic EPS | 0.03 | 0.25 | 0.35 | 0.30 | 0.24 |
| EPS Diluted | 0.00 | 0.40 | 0.56 | 0.48 | 0.38 |
| Normalized Diluted EPS | 0.03 | 0.25 | 0.35 | 0.30 | 0.24 |
| Average Basic Shares Outstanding | 550.89M | 466.94M | 387.03M | 342.84M | 337.75M |
| Average Diluted Shares Outstanding | 550.92M | 466.97M | 387.17M | 342.98M | 338.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |